Literature DB >> 8959048

Neurochemical analysis of the psychotoxicity of methamphetamine and cocaine by microdialysis in the rat brain.

A Shimada1, K Yamaguchi, T Yanagita.   

Abstract

To examine the neurochemical mechanism underlying the development of psychotoxicity by methamphetamine and cocaine, the levels of dopamine, serotonin and their metabolites were determined by in vivo microdialysis in the brains of freely moving rats. Methamphetamine (0.5 mg/kg, s.c.) or cocaine (10 mg/kg, i.p.) was repeatedly administered for 8 to 21 experiment days, and after confirming the development of sensitization to the stimulating effect of the drugs on spontaneous motor activity, a microdialysis probe was implanted into the nucleus accumbens (N.Acc.) or striatum of the brain of the treated rats. Then, each test drug was readministered to the rats and dopamine and DOPAC or serotonin and 5-HIAA concentrations were determined. In the N.Acc. of untreated control rats, methamphetamine increased dopamine to about 4 times the preadministration value along with a decrease of DOPAC. Methamphetamine also increased serotonin to about twice the preadministration value along with no change in 5-HIAA. Cocaine increased dopamine to about 4 times along with a slight decrease in DOPAC. In the treated rats as compared with the untreated rats, the increasing effect of methamphetamine on dopamine in the N.Acc. was enhanced but that of cocaine was not. Also, the serotonin levels were lower than in the untreated rats and 5-HIAA was unchanged. In the striatum of untreated rats, methamphetamine increased dopamine to about 3 times the preadministration value along with a slight decrease in DOPAC. In the treated rats, the increasing effect of methamphetamine on dopamine in the striatum was enhanced, and the DOPAC level was higher than in the treated rats. The present study suggests that the dopamine level at the N.Acc. does not necessarily reflect the sensitization to spontaneous motor activity, and that enhancement of the motor activity does not seem to be the best model for psychotoxic manifestation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959048     DOI: 10.1111/j.1749-6632.1996.tb17456.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Distinct neurochemical adaptations within the nucleus accumbens produced by a history of self-administered vs non-contingently administered intravenous methamphetamine.

Authors:  Kevin D Lominac; Arianne D Sacramento; Karen K Szumlinski; Tod E Kippin
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

2.  An in vivo microdialysis assessment of concurrent MDMA and cocaine administration in Sprague-Dawley rats.

Authors:  John J Panos; Lisa E Baker
Journal:  Psychopharmacology (Berl)       Date:  2010-01-30       Impact factor: 4.530

3.  Powerful behavioral interactions between methamphetamine and morphine.

Authors:  Keith A Trujillo; Monique L Smith; Melissa M Guaderrama
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

4.  Brief exposure to methamphetamine (METH) and phencyclidine (PCP) during late development leads to long-term learning deficits in rats.

Authors:  Ilsun M White; Takehiro Minamoto; Joseph R Odell; Joseph Mayhorn; Wesley White
Journal:  Brain Res       Date:  2009-02-24       Impact factor: 3.252

5.  The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization.

Authors:  Marlaina R Stocco; Ahmed A El-Sherbeni; Bin Zhao; Maria Novalen; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2021-03-01       Impact factor: 4.530

6.  Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats.

Authors:  Jean Lud Cadet; Christie Brannock; Irina N Krasnova; Bruce Ladenheim; Michael T McCoy; Jenny Chou; Elin Lehrmann; William H Wood; Kevin G Becker; Yun Wang
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.